Aptahem AB (publ) (NGM:APTA)

Market Cap	8.20M
Revenue (ttm)	3.77M
Net Income (ttm)	-8.57M
Shares Out	12.50M
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	627
Average Volume	25,879
Open	0.788
Previous Close	0.790
Day's Range	0.740 - 0.788
52-Week Range	0.614 - 5.900
Beta	-0.07
RSI	32.33
Earnings Date	Feb 12, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, an increase of 43.39% compared to the previous year's 2.63 million. Losses were -8.57 million, -22.90% less than in 2023.